Inhibitors of EZH2
First Claim
Patent Images
1. A compound selected from the group consisting of:
- N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-{(1R)-1-[trans-4-(3-methoxyazetidin-1-yl)cyclohexyl]ethyl}-4-methylthiophene-3-carboxamide;
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to compounds that inhibit activity of the histone lysine N-methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.
-
Citations
5 Claims
-
1. A compound selected from the group consisting of:
N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-{(1R)-1-[trans-4-(3-methoxyazetidin-1-yl)cyclohexyl]ethyl}-4-methylthiophene-3-carboxamide; - View Dependent Claims (2, 3)
-
4. A pharmaceutical composition comprising a compound selected from the group consisting of:
N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-{(1R)-1-[trans-4-(3-methoxyazetidin-1-yl)cyclohexyl]ethyl}-4-methylthiophene-3-carboxamide;
-
5. A method of treating cancer, wherein the cancer is diffuse large B-cell lymphoma, comprising administering to a patient in need thereof, an effective amount of a compound selected from the group consisting of:
N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-{(1R)-1-[trans-4-(3-methoxyazetidin-1-yl)cyclohexyl]ethyl}-4-methylthiophene-3-carboxamide;
Specification